Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer

• DOI: 10.1097/coc.0b013e31827e52a3
• Publication Date: 2013-03-05T14:10:21Z
• Authors: Melissa P. Mitchell; Mirna Abboud; Cathy Eng; A. Sam Beddar; Sunil Krishnan; Marc E. Delclos; Christopher H. Crane; Prajnan Das
• Keywords: Mucositis

To evaluate toxicity, local control, and survival in anal cancer patients treated with intensity-modulated radiation therapy (IMRT) concurrent chemotherapy.Sixty-five were at a single institution IMRT chemotherapy for localized squamous cell carcinoma of the canal. Radiotherapy was delivered simultaneous integrated boost technique, dose based on T stage. The median to primary tumor pelvis 54 Gy (range, 50 58.8 Gy) 45 40.5 50.4 Gy), respectively. most common regimens 5-fluorouracil cisplatin (75%), capecitabine oxaliplatin (11%), mitomycin C (5%).The percentage Tx, T1, T2, T3, T4 disease 8%, 17%, 49%, 15%, 11%, N0, N1, N2, N3 46%, 9%, 28%, Ninety-one percent completed treatment without break. Grade 3 gastrointestinal toxicity occurred moist desquamation beyond perianal area 17%. use vaginal dilator during simulation seemed lower rates acute skin late sexual toxicity. With follow-up 19 months, 2-year distant control both 93%. overall disease-free 96% 86%, respectively.Concurrent well tolerated, associated low excellent survival, survival.